East China Pharmaceutical (000963) Annual Report Review: Improving the layout of regeneration+HA+ botulism pipelines, the ability to contribute to the profitability of the medical and aesthetic business is expected to continue to improve

Incident: The company released its 2023 annual report. In 23, the company achieved operating income of 40.624 billion yuan/yoy +7.71%, and realized net profit of 2,839 million yuan/yoy +13.59%; single Q4

信達證券Apr 18 18:41

Depth* Company* East China Pharmaceutical (000963): Medicine and Aesthetics Maintain Rapid Growth, Pharmaceutical Industry Innovation Achievements Gradually Realize

Huadong Pharmaceutical achieved operating income of 40.624 billion yuan in 2023, an increase of 7.71% over the previous year, and achieved net profit of 2,839 billion yuan to mother, an increase of 13.59% over the previous year. The company's medical and aesthetic business continues to grow rapidly, and the pharmaceutical industry

中銀證券Apr 18 18:21

Bank of China Securities released a research report on April 18 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) maintaining steady growth in performance and maintaining investment in

Bank of China Securities released a research report on April 18 stating that Huadong Pharmaceutical (000963.SZ) was given a purchase rating. The main reasons for the rating include: 1) maintaining steady growth in performance and maintaining investment in R&D; 2) the pharmaceutical industry sector's performance is growing steadily, and innovative results are gradually being realized; 3) the medical and aesthetic business has maintained rapid growth, and the medical and aesthetic product matrix continues to expand. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 18 16:37

Huadong Pharmaceutical (000963): Profit growth accelerated in 4Q23

Net profit growth accelerated in 4Q23, maintaining that the purchase rating company published its annual report for the year 23 on 4/17, achieved revenue of 406.2 yuan (+7.7% yoy) in '23, and net profit of 2.84 billion yuan (+13).

華泰證券Apr 18 09:51

Huadong Medicine's 2023 Profit Jumps 14%

Huadong Medicine's (SHE:000963) attributable profit rose 14% to 2.84 billion yuan in 2023 from 2.50 billion yuan in 2022, according to a Thursday filing with the Shenzhen bourse. Earnings per share at

MT NewswiresApr 18 09:04

Express News | Huadong Pharmaceutical: Net profit of 2,839 billion yuan in 2023 increased 13.59% year-on-year, and plans to distribute 10 to 5.8 yuan

BreakingsApr 17 20:30